Compare BridgeBio Pharma Inc (BBIO) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs NRG Energy Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while NRG Energy Inc trades at $120.38 (market cap $24.83B). The key difference: NRG Energy Inc is the larger of the two by market cap, and NRG Energy Inc pays a 1.61% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NRG | |
|---|---|---|
Market Cap | $16.61B | $24.83B |
Sector | Health | Utilities |
52-Week High | $90.17 | $184.03 |
52-Week Low | $47.29 | $117.04 |
Enterprise Value | $18.16B | $48.79B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
NRG Energy trades at $118.13, down 0.77% on the day, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. The company reported Q2 2026 adjusted EBITDA of $1.2 billion, up 34% year-over-year, and is advancing a 1.2-GW Texas data-center power project to drive growth. Valuation metrics show a P/E of 30.76 and P/S of 0.72, with a net income margin of 2.56% for 2025.
The outlook is mixed: strong analyst consensus (69% buy ratings) and a $207.83 price target suggest upside, but technical weakness, rising debt, and execution risks on new projects pose challenges. Revenue growth to $33.1B in 2026 and strategic investments in data center demand support long-term potential, though interest costs and leverage require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
